Authorization for Moderna’s (MRNA) COVID-19 vaccine for ages 12-17 was put on hold Friday in light of concerns over a rare side effect known as myocarditis, or a heart inflammation.
The U.S. Food and Drug Administration decision gives Pfizer’s (PFE), which has a similar technology, an advantage in the market. In advisory panel discussions prior to Pfizer’s authorization for adolescents, the myocarditis risks were raised, but ultimately the panel decided the benefits outweigh the risks. As a…
Source link
